신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가

신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가

The in vitro antibacterial activities of new carbapenem. CRB 529, 535, 538, 545 and 550 with meropenem and imipenem were compared. CRB 529. 535, 538, 545 and 550 proved to have a broad an tibacterial spectrum. Its in vitro activity against standard 20 strains was almost the same as that of imipenem...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Yaghag-hoi-ji 1995-06, Vol.39 (3), p.215-222
Hauptverfasser: 민관기(Kwan Kee Min), 김준겸(Joon Kyum Kim), 이홍우(Hong Woo Lee), 김정우(Jeong Woo Kim)
Format: Artikel
Sprache:kor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 222
container_issue 3
container_start_page 215
container_title Yaghag-hoi-ji
container_volume 39
creator 민관기(Kwan Kee Min)
김준겸(Joon Kyum Kim)
이홍우(Hong Woo Lee)
김정우(Jeong Woo Kim)
description The in vitro antibacterial activities of new carbapenem. CRB 529, 535, 538, 545 and 550 with meropenem and imipenem were compared. CRB 529. 535, 538, 545 and 550 proved to have a broad an tibacterial spectrum. Its in vitro activity against standard 20 strains was almost the same as that of imipenem and slightly higher than that of meropenem. However. against clinical isolated P. aeruginosa, CRB 529, 535, 538, 545 and 550 showed significantly higher activity than imipenem, and also CRB 529, 535, 538, 545 and 550 showed almost the same activity than imipenem and meropenem against 82 clinical isolated strains including S. aureus (MRSA), S. aureus (MSSA), E. faecalis, E. facium, E. coli, P. aeruginosa, K. pneumonia, P. mirabiris, P. stuartii, M. morganii, C. freundii, E. cloacae, S. marcescens and A. calcoaceticus var. anitratus. The stability of CRB 529, 535, 538, 545 and 550 against porcine renal dehydropeptidase-I(DHP-1) was 10 folds higher than that of imipenem and was 3 folds higher than that of meropenem.
format Article
fullrecord <record><control><sourceid>kyobo_kisti</sourceid><recordid>TN_cdi_kisti_ndsl_JAKO199511919470211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4010023998440</sourcerecordid><originalsourceid>FETCH-LOGICAL-k600-cc47008f63d0ad48f327a75de4830534794c866dbb57656d35a2a0edfa0b228a3</originalsourceid><addsrcrecordid>eNpNjD1Lw0Achw9RsNR-h1vcDPzv_W6swfdCQTq4hUvuAqW1kaaLWxEX6dBJ7FAhi6MgEuh3StPvYIsOLs_vNzw8e6hBmWaB4ULtowYwpQIjhDxErTzvx8AkVVox0UB39ayoVksc2nFsH_zI3-N6Waznz_V3icPbUyyoOcGCiR30Fnz3BNTvC1zPlpu3RVVO108l3rx-VqtiXXzgzfyl-poeoYPUDnPf-tsm6p2f9cLLoNO9uArbnWAgAYIk4QpAp5I5sI7rlFFllXCeawaCcWV4oqV0cSyUFNIxYakF71ILMaXasiY6_s0O-vmkH41cPoyu2zddYowgxBCz7VNC_nmPWZxFcZYNEj-a-HHEgQBQZozmHNgPCiBjMw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가</title><source>Alma/SFX Local Collection</source><creator>민관기(Kwan Kee Min) ; 김준겸(Joon Kyum Kim) ; 이홍우(Hong Woo Lee) ; 김정우(Jeong Woo Kim)</creator><creatorcontrib>민관기(Kwan Kee Min) ; 김준겸(Joon Kyum Kim) ; 이홍우(Hong Woo Lee) ; 김정우(Jeong Woo Kim)</creatorcontrib><description>The in vitro antibacterial activities of new carbapenem. CRB 529, 535, 538, 545 and 550 with meropenem and imipenem were compared. CRB 529. 535, 538, 545 and 550 proved to have a broad an tibacterial spectrum. Its in vitro activity against standard 20 strains was almost the same as that of imipenem and slightly higher than that of meropenem. However. against clinical isolated P. aeruginosa, CRB 529, 535, 538, 545 and 550 showed significantly higher activity than imipenem, and also CRB 529, 535, 538, 545 and 550 showed almost the same activity than imipenem and meropenem against 82 clinical isolated strains including S. aureus (MRSA), S. aureus (MSSA), E. faecalis, E. facium, E. coli, P. aeruginosa, K. pneumonia, P. mirabiris, P. stuartii, M. morganii, C. freundii, E. cloacae, S. marcescens and A. calcoaceticus var. anitratus. The stability of CRB 529, 535, 538, 545 and 550 against porcine renal dehydropeptidase-I(DHP-1) was 10 folds higher than that of imipenem and was 3 folds higher than that of meropenem.</description><identifier>ISSN: 0377-9556</identifier><identifier>EISSN: 2383-9457</identifier><language>kor</language><publisher>The Pharmaceutical Society Of Korea</publisher><ispartof>Yaghag-hoi-ji, 1995-06, Vol.39 (3), p.215-222</ispartof><rights>COPYRIGHT(C) KYOBO BOOK CENTRE ALL RIGHTS RESERVED</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885</link.rule.ids></links><search><creatorcontrib>민관기(Kwan Kee Min)</creatorcontrib><creatorcontrib>김준겸(Joon Kyum Kim)</creatorcontrib><creatorcontrib>이홍우(Hong Woo Lee)</creatorcontrib><creatorcontrib>김정우(Jeong Woo Kim)</creatorcontrib><title>신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가</title><title>Yaghag-hoi-ji</title><addtitle>Yakhak hoeji</addtitle><description>The in vitro antibacterial activities of new carbapenem. CRB 529, 535, 538, 545 and 550 with meropenem and imipenem were compared. CRB 529. 535, 538, 545 and 550 proved to have a broad an tibacterial spectrum. Its in vitro activity against standard 20 strains was almost the same as that of imipenem and slightly higher than that of meropenem. However. against clinical isolated P. aeruginosa, CRB 529, 535, 538, 545 and 550 showed significantly higher activity than imipenem, and also CRB 529, 535, 538, 545 and 550 showed almost the same activity than imipenem and meropenem against 82 clinical isolated strains including S. aureus (MRSA), S. aureus (MSSA), E. faecalis, E. facium, E. coli, P. aeruginosa, K. pneumonia, P. mirabiris, P. stuartii, M. morganii, C. freundii, E. cloacae, S. marcescens and A. calcoaceticus var. anitratus. The stability of CRB 529, 535, 538, 545 and 550 against porcine renal dehydropeptidase-I(DHP-1) was 10 folds higher than that of imipenem and was 3 folds higher than that of meropenem.</description><issn>0377-9556</issn><issn>2383-9457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>JDI</sourceid><recordid>eNpNjD1Lw0Achw9RsNR-h1vcDPzv_W6swfdCQTq4hUvuAqW1kaaLWxEX6dBJ7FAhi6MgEuh3StPvYIsOLs_vNzw8e6hBmWaB4ULtowYwpQIjhDxErTzvx8AkVVox0UB39ayoVksc2nFsH_zI3-N6Waznz_V3icPbUyyoOcGCiR30Fnz3BNTvC1zPlpu3RVVO108l3rx-VqtiXXzgzfyl-poeoYPUDnPf-tsm6p2f9cLLoNO9uArbnWAgAYIk4QpAp5I5sI7rlFFllXCeawaCcWV4oqV0cSyUFNIxYakF71ILMaXasiY6_s0O-vmkH41cPoyu2zddYowgxBCz7VNC_nmPWZxFcZYNEj-a-HHEgQBQZozmHNgPCiBjMw</recordid><startdate>19950630</startdate><enddate>19950630</enddate><creator>민관기(Kwan Kee Min)</creator><creator>김준겸(Joon Kyum Kim)</creator><creator>이홍우(Hong Woo Lee)</creator><creator>김정우(Jeong Woo Kim)</creator><general>The Pharmaceutical Society Of Korea</general><general>대한약학회</general><scope>P5Y</scope><scope>SSSTE</scope><scope>JDI</scope></search><sort><creationdate>19950630</creationdate><title>신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가</title><author>민관기(Kwan Kee Min) ; 김준겸(Joon Kyum Kim) ; 이홍우(Hong Woo Lee) ; 김정우(Jeong Woo Kim)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-k600-cc47008f63d0ad48f327a75de4830534794c866dbb57656d35a2a0edfa0b228a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>1995</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>민관기(Kwan Kee Min)</creatorcontrib><creatorcontrib>김준겸(Joon Kyum Kim)</creatorcontrib><creatorcontrib>이홍우(Hong Woo Lee)</creatorcontrib><creatorcontrib>김정우(Jeong Woo Kim)</creatorcontrib><collection>Kyobo Scholar (교보스콜라)</collection><collection>Scholar(스콜라)</collection><collection>KoreaScience</collection><jtitle>Yaghag-hoi-ji</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>민관기(Kwan Kee Min)</au><au>김준겸(Joon Kyum Kim)</au><au>이홍우(Hong Woo Lee)</au><au>김정우(Jeong Woo Kim)</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가</atitle><jtitle>Yaghag-hoi-ji</jtitle><addtitle>Yakhak hoeji</addtitle><date>1995-06-30</date><risdate>1995</risdate><volume>39</volume><issue>3</issue><spage>215</spage><epage>222</epage><pages>215-222</pages><issn>0377-9556</issn><eissn>2383-9457</eissn><abstract>The in vitro antibacterial activities of new carbapenem. CRB 529, 535, 538, 545 and 550 with meropenem and imipenem were compared. CRB 529. 535, 538, 545 and 550 proved to have a broad an tibacterial spectrum. Its in vitro activity against standard 20 strains was almost the same as that of imipenem and slightly higher than that of meropenem. However. against clinical isolated P. aeruginosa, CRB 529, 535, 538, 545 and 550 showed significantly higher activity than imipenem, and also CRB 529, 535, 538, 545 and 550 showed almost the same activity than imipenem and meropenem against 82 clinical isolated strains including S. aureus (MRSA), S. aureus (MSSA), E. faecalis, E. facium, E. coli, P. aeruginosa, K. pneumonia, P. mirabiris, P. stuartii, M. morganii, C. freundii, E. cloacae, S. marcescens and A. calcoaceticus var. anitratus. The stability of CRB 529, 535, 538, 545 and 550 against porcine renal dehydropeptidase-I(DHP-1) was 10 folds higher than that of imipenem and was 3 folds higher than that of meropenem.</abstract><pub>The Pharmaceutical Society Of Korea</pub><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0377-9556
ispartof Yaghag-hoi-ji, 1995-06, Vol.39 (3), p.215-222
issn 0377-9556
2383-9457
language kor
recordid cdi_kisti_ndsl_JAKO199511919470211
source Alma/SFX Local Collection
title 신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A24%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kyobo_kisti&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%EC%8B%A0%EA%B7%9C%20Carbapenem%20%EC%9C%A0%EB%8F%84%EC%B2%B4%20CRB%20529,%20535,%20538,%20545,%20550%EC%9D%98%20%EC%8B%9C%ED%97%98%EA%B4%80%EB%82%B4%20%ED%95%AD%EA%B7%A0%EB%A0%A5%20%ED%8F%89%EA%B0%80&rft.jtitle=Yaghag-hoi-ji&rft.au=%EB%AF%BC%EA%B4%80%EA%B8%B0(Kwan%20Kee%20Min)&rft.date=1995-06-30&rft.volume=39&rft.issue=3&rft.spage=215&rft.epage=222&rft.pages=215-222&rft.issn=0377-9556&rft.eissn=2383-9457&rft_id=info:doi/&rft_dat=%3Ckyobo_kisti%3E4010023998440%3C/kyobo_kisti%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true